Alnylam Pharmaceuticals | ALNY - Gross Profit On Sales



Alnylam Pharmaceuticals reported $630.74M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.83M 19.91M Jun/2025
Agios Pharmaceuticals USD 10.75M 3.11M Jun/2025
Alnylam Pharmaceuticals USD 630.74M 107.59M Jun/2025
Amgen USD 6.17B 624M Jun/2025
Arrowhead Research 27.77M 514.94M Jun/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Incyte USD 1.14B 151.67M Jun/2025
Ionis Pharmaceuticals USD 448M 317.85M Jun/2025
Moderna USD 18M 1000K Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
Novartis USD 11.52B 1.27B Jun/2025
PTC Therapeutics USD 163.39M 999.84M Jun/2025
Regeneron Pharmaceuticals USD 3.15B 581M Jun/2025
Sanofi EUR 7.74B 2.38B Jun/2025
Sarepta Therapeutics USD 457.87M 149.43M Jun/2025
Takeda JPY 722.01B 50.69B Jun/2025
Tectonic Therapeutic 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 143.49M 32.86M Jun/2025
Vertex Pharmaceuticals USD 2.56B 150M Jun/2025
Xencor 43.61M 10.88M Jun/2025